Patients with large (≥ 2 cm) HR+, HER2-negative breast cancers who were BCS noncandidates were assigned neoadjuvant therapy based on Recurrence Score results: RS < 11 received hormonal therapy, RS ≥ 26 received chemotherapy, and RS11–25 were randomized to hormonal therapy or chemotherapy. Here, ERBB2 is linked to breast carcinoma.